Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications

IMPORTANCE: Postmarket analysis of individuals who receive nirmatrelvir and ritonavir (Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in published clinical trials. OBJECTIVE: To examine the association of nirmatrelvir and ritonavir with prevention of deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dormuth, Colin R., Kim, Jason D., Fisher, Anat, Piszczek, Jolanta, Kuo, I Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546233/
https://www.ncbi.nlm.nih.gov/pubmed/37782496
http://dx.doi.org/10.1001/jamanetworkopen.2023.36678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546233/
https://www.ncbi.nlm.nih.gov/pubmed/37782496
http://dx.doi.org/10.1001/jamanetworkopen.2023.36678

Ejemplares similares